GlassScriptPhysician profile
Derek A Lafont
NPI 1013980184
$24,259.58
in general payments reported to CMS, 2019-2025
74 companies · $5,257 in 2025
The $5,257 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,501 · 2022: $4,400 · 2023: $6,355 · 2024: $6,747 · 2025: $5,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Long Term Medical Supply Or Device Loan: $2,164 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,093 · Education: $1,096 · Consulting Fee: $960 · Travel and Lodging: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,466.70 |
| Long Term Medical Supply Or Device Loan | $2,163.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,092.50 |
| Education | $1,095.99 |
| Consulting Fee | $960.00 |
| Travel and Lodging | $579.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,627.24 | 2021-2025 | |
| Seagen INC. | $3,134.62 | 2021-2025 | Tukysa, Padcev, Adcetris |
| Pfizer INC. | $2,604.89 | 2022-2025 | |
| Janssen Biotech, INC. | $1,023.74 | 2021-2025 | Darzalex, Tecvayli, Erleada |
| Daiichi Sankyo INC. | $981.30 | 2021-2025 | Enhertu, Injectafer, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $863.05 | 2021-2025 | Calquence, Tagrisso, Lynparza |
| Merck Sharp & Dohme LLC | $769.40 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $750.84 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $655.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $650.45 | 2021-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $585.68 | 2021-2025 | Avastin, Alecensa, Tecentriq |
| Astellas Pharma US INC | $564.26 | 2021-2025 | Vyloy, Xospata, Xtandi |
| Gilead Sciences, INC. | $505.64 | 2021-2025 | Trodelvy |
| Exelixis INC. | $414.38 | 2021-2025 | Cabometyx |
| Celgene Corporation | $406.52 | 2021-2024 | Reblozyl, Opdualag, Pomalyst |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $385.71 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Regeneron Healthcare Solutions, INC. | $338.97 | 2021-2025 | Libtayo, Lynozyfic |
| Stemline Therapeutics INC. | $326.70 | 2023-2025 | Orserdu, Elzonris |
| Abbvie INC. | $321.04 | 2021-2025 | |
| Taiho Oncology, INC. | $295.06 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $269.90 | 2021-2023 | Imbruvica, Epkinly |
| Glaxosmithkline, LLC. | $252.04 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Puma Biotechnology, INC. | $235.89 | 2021-2025 | Nerlynx |
| Bayer Healthcare Pharmaceuticals INC. | $227.68 | 2022-2025 | |
| Eisai INC. | $211.98 | 2021-2025 | |
| Array Biopharma INC | $204.83 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Kite Pharma, INC. | $202.64 | 2021-2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $167.98 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.61 | 2021-2025 | Fruzaqla, Iclusig |
| Acrotech Biopharma INC. | $155.42 | 2021-2025 | Beleodaq |
| Karyopharm Therapeutics INC. | $143.63 | 2021-2024 | Xpovio |
| Beone Medicines USA, INC. | $136.71 | 2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $134.20 | 2021-2025 | Qinlock, Tgct |
| Tersera Therapeutics LLC | $133.59 | 2021-2025 | Quzyttir |
| Aveo Pharmaceuticals, INC. | $133.30 | 2021-2025 | Fotivda |
| Blueprint Medicines Corporation | $128.87 | 2021-2025 | Ayvakit |
| Genmab U.S., INC. | $109.29 | 2023-2025 | Epkinly |
| Servier Pharmaceuticals LLC | $107.70 | 2021-2024 | |
| G1 Therapeutics, INC. | $106.97 | 2022-2023 | Cosela |
| Emd Serono, INC. | $101.71 | 2023-2025 | Bavencio |
| Beigene USA, INC. | $98.93 | 2022-2024 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $96.24 | 2022-2025 | Onivyde, Somatuline Depot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.41 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $94.41 | 2021-2024 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $86.21 | 2022-2025 | |
| Mirati Therapeutics, INC. | $85.85 | 2023-2024 | Krazati |
| Tg Therapeutics, INC. | $81.57 | 2021-2023 | |
| Sobi, INC | $77.89 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $77.36 | 2022-2025 | Monoferric |
| Geron Corporation | $67.84 | 2025 | Rytelo |
| Alexion Pharmaceuticals, INC. | $67.42 | 2022-2024 | Ultomiris |
| Coherus Oncology, INC. | $67.12 | 2021-2024 | |
| Iovance Biotherapeutics, INC. | $62.90 | 2025 | Amtagvi |
| Epizyme, INC. | $57.72 | 2021-2022 | |
| Fennec Pharmaceuticals, INC. | $54.36 | 2024 | Pedmark |
| Azurity Pharmaceuticals, INC. | $46.29 | 2024-2025 | Danziten, Vivimusta |
| Spectrum Pharmaceuticals INC. | $45.29 | 2023-2024 | Rolvedon |
| Heron Therapeutics, INC. | $40.41 | 2023 | Cinvanti |
| Fresenius Kabi USA, LLC | $40.03 | 2024 | Stimufend |
| Adaptive Biotechnologies Corporation | $39.80 | 2021-2022 | |
| Morphosys, US INC. | $38.34 | 2021-2022 | |
| Pharmaessentia USA Corporation | $38.25 | 2022-2025 | Besremi |
| Cti Biopharma Corp. | $36.87 | 2022-2023 | Vonjo |
| Amgen INC. | $33.54 | 2023 | Lumakras, Blincyto, Kyprolis |
| Eusa Pharma (US) LLC | $29.22 | 2022 | |
| Verity Pharmaceuticals INC. | $25.07 | 2025 | Trelstar |
| Sumitomo Pharma America, INC. | $22.54 | 2024 | Orgovyx |
| Syndax Pharmaceuticals, INC. | $20.83 | 2025 | |
| Amag Pharmaceuticals, INC. | $19.69 | 2022 | |
| Myriad Genetic Laboratories, INC. | $19.53 | 2023 | Precisetumor |
| Amneal Pharmaceuticals LLC | $19.09 | 2024 | Avastin |
| Immunocore Limited | $19.05 | 2025 | Kimmtrak |
| Secura Bio, INC. | $15.42 | 2022 | |
| Myovant Sciences INC. | $12.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Lafont listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.